SAREPTA THERAPEUTICS, INC. (SRPT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 502.91M USD | Liabilities, Current |
| Cash and equivalents | 571.15M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 376.82M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 904.27M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $502.91M | $571.15M | (m) | $376.82M | $904.27M | (m) |
| 2026-03-31 | (m) | $499.16M | $464.45M | (m) | $394.82M | $1.00B | (m) |
| 2025-12-31 | (m) | $1.10B | $801.28M | (m) | $398.23M | $914.74M | (m) |
| 2025-09-30 | (m) | $921.42M | $613.08M | (m) | $395.74M | $1.08B | (m) |
| 2025-06-30 | (m) | $919.95M | $510.60M | (m) | $527.29M | $994.04M | (m) |
| 2025-03-31 | (m) | $605.59M | $240.87M | (m) | $659.37M | $941.43M | (m) |
| 2024-12-31 | (m) | $731.68M | $1.10B | (m) | $601.99M | $749.96M | (m) |
| 2024-09-30 | (m) | $699.49M | $197.85M | (m) | $434.52M | $565.92M | (m) |
| 2024-06-30 | $1.82B | $688.49M | $383.62M | $1.08B | $360.00M | $485.80M | 2.64× |
| 2024-03-31 | $1.77B | $608.71M | $427.29M | $963.45M | $378.81M | $373.53M | 2.91× |
| 2023-12-31 | $2.08B | $653.66M | $428.43M | $1.25B | $400.33M | $322.86M | 3.18× |
| 2023-09-30 | $2.05B | $450.74M | $541.93M | $1.19B | $318.86M | $244.01M | 4.55× |
| 2023-06-30 | $2.10B | $498.65M | $851.93M | $1.01B | $236.81M | $226.88M | 4.21× |
| 2023-03-31 | $2.11B | $536.88M | $871.67M | $1.01B | $223.84M | $202.68M | 3.92× |
| 2022-12-31 | $2.20B | $619.60M | $966.78M | $1.02B | $214.63M | $203.97M | 3.56× |
| 2022-09-30 | $2.27B | $602.92M | $1.04B | $1.03B | $201.51M | $221.19M | 3.77× |
| 2022-06-30 | $2.13B | $545.57M | $868.57M | $1.06B | $203.85M | $208.09M | 3.91× |
| 2022-03-31 | $2.19B | $454.96M | $1.23B | $779.55M | $178.19M | $199.00M | 4.82× |
| 2021-12-31 | $2.27B | $452.73M | $2.12B | $0.00 | $152.99M | $186.21M | 5.01× |
| 2021-09-30 | (m) | $373.44M | $1.60B | (m) | $149.79M | $288.47M | (m) |
| 2021-06-30 | $1.85B | $425.02M | $1.70B | $30.00M | $127.52M | $268.76M | 4.36× |
| 2021-03-31 | $1.86B | $364.74M | $1.48B | $256.00M | $118.20M | $240.33M | 5.09× |
| 2020-12-31 | $2.04B | $416.03M | $1.50B | $435.92M | $101.34M | $231.96M | 4.90× |
| 2020-09-30 | $1.94B | $378.39M | $1.47B | $341.47M | $121.83M | $220.12M | 5.12× |
| 2020-06-30 | $2.17B | $354.90M | $1.64B | $421.35M | $104.03M | $179.65M | 6.10× |
| 2020-03-31 | $2.28B | $306.43M | $1.76B | $406.94M | $106.88M | $173.17M | 7.43× |
| 2019-12-31 | $1.22B | $264.77M | $835.08M | $289.67M | $90.88M | $171.38M | 4.59× |
| 2019-09-30 | $1.12B | $215.86M | $724.83M | $324.06M | $68.03M | $166.36M | 5.17× |
| 2019-06-30 | $1.16B | $162.09M | $808.59M | $294.48M | $56.98M | $156.57M | 7.16× |
| 2019-03-31 | $1.39B | $137.37M | $732.19M | $612.02M | $50.51M | $140.47M | 10.15× |
| 2018-12-31 | $1.22B | $173.69M | $370.83M | $803.08M | $49.04M | $125.44M | 7.04× |
| 2018-09-30 | (m) | $114.39M | $209.70M | (m) | $48.60M | $115.82M | (m) |
| 2018-06-30 | (m) | $104.69M | $410.38M | (m) | $42.98M | $104.13M | (m) |
| 2018-03-31 | (m) | $91.20M | $557.23M | (m) | $39.85M | $99.38M | (m) |
| 2017-12-31 | (m) | $88.33M | $599.69M | (m) | $29.47M | $83.61M | (m) |
| 2017-09-30 | (m) | $70.47M | $617.63M | (m) | $24.75M | $64.69M | (m) |
| 2017-06-30 | (m) | $65.96M | $168.35M | (m) | $17.79M | $41.75M | (m) |
| 2017-03-31 | (m) | $74.63M | $274.72M | (m) | $12.28M | $30.45M | (m) |
| 2016-12-31 | (m) | $75.42M | $122.42M | (m) | $5.23M | $12.81M | (m) |
| 2016-09-30 | (m) | $64.93M | $395.14M | (m) | $3.99M | $2.92M | (m) |
| 2016-06-30 | (m) | $66.93M | $111.82M | (m) | $3.98M | (m) | (m) |
| 2016-03-31 | (m) | $55.16M | $38.00M | (m) | $3.99M | (m) | (m) |
| 2015-12-31 | (m) | $62.29M | $80.30M | (m) | $3.98M | (m) | (m) |
| 2015-09-30 | (m) | $37.67M | $55.82M | (m) | $2.73M | (m) | (m) |
| 2015-06-30 | (m) | $38.96M | $69.54M | (m) | $2.42M | (m) | (m) |
| 2015-03-31 | (m) | $33.91M | $74.44M | (m) | $2.42M | (m) | (m) |
| 2014-12-31 | (m) | $36.87M | $73.55M | (m) | $2.42M | (m) | (m) |
| 2014-09-30 | (m) | $22.73M | $52.30M | (m) | $3.36M | (m) | (m) |
| 2014-06-30 | (m) | $29.40M | $102.75M | (m) | $5.23M | (m) | (m) |
| 2014-03-31 | (m) | $37.76M | $49.10M | (m) | $7.85M | (m) | (m) |
| 2013-12-31 | (m) | $35.97M | $256.96M | (m) | $3.53M | (m) | (m) |
| 2013-09-30 | (m) | $51.10M | $273.64M | (m) | $6.72M | (m) | (m) |
| 2013-06-30 | (m) | $92.43M | $156.19M | (m) | $3.79M | (m) | (m) |
| 2013-03-31 | (m) | $103.66M | $167.92M | (m) | $5.65M | (m) | (m) |
| 2012-12-31 | (m) | $78.89M | $187.66M | (m) | $4.71M | (m) | (m) |
| 2012-09-30 | (m) | $55.20M | $37.99M | (m) | $2.47M | (m) | (m) |
| 2012-06-30 | (m) | $17.13M | $24.49M | (m) | $7.18M | (m) | (m) |
| 2012-03-31 | (m) | $29.92M | $30.57M | (m) | $5.13M | (m) | (m) |
| 2011-12-31 | (m) | $20.60M | $39.90M | (m) | $3.63M | (m) | (m) |
| 2011-09-30 | (m) | $26.53M | $46.36M | (m) | $4.27M | (m) | (m) |
| 2011-06-30 | (m) | $36.94M | $54.19M | (m) | $10.89M | (m) | (m) |
| 2011-03-31 | (m) | (m) | $23.28M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $45.86M | $33.59M | (m) | $3.22M | (m) | (m) |
| 2010-09-30 | (m) | (m) | $35.97M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $36.74M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $48.27M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $11.19M | (m) | (m) | (m) | (m) |
| 1980-07-21 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |